Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
The FDA has issued a warning letter to a Bayer finished products plant in Germany, where it says poor cleaning led to product cross-contamination.
The EMA has been probing the safety of Allergan’s Esmya since December. Now it's advising no new patients start taking it until the investigation wraps up.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
AmerisourceBergen has received a grand jury subpoena to supply info to the DOJ about its testing of a syringe made at its PharMEDium lab in Tennessee.
Here's some of the other news we're following today.
A new front has opened in the fight to make the pharma industry responsible for disposing of unused meds, this time in New York.
From the FDA’s point of view, OTC drugs and weedkiller just don’t mix. That is the message delivered in a newly posted warning letter to an Iowa company.
The FDA has decided that Fresenius Kabi’s retrieval of more than 200,000 syringes rises to the level of a Class I recall.
Five months after blocking the products of Prosana Distribuciones from the U.S., the FDA has issued a warning letter for the Mexican company.
A Fresenius Kabi cancer drug plant savaged by the FDA in the past for hiding serious drug testing issues has been slapped with a new warning letter.
Disasters, both natural and manmade, wreaked havoc on pharma supply chains this year, and pharma can expect the threats to only get worse.